Abstract: The acute myeloid leukemias are genetically a diverse group of neoplasm with varied clinical behavior and response to treatment. Advances in immunophenotyping, cytogenetics and molecular genetics have resulted in better understanding of their genesis. Risk stratification of different variants is now emerging. Therapy strategies are now increasingly being developed considering the inherent biological behavior of the different subtypes. It is anticipated that in the future, deeper secrets of these once fatal diseases will be unraveled by advances in newer genomic techniques. It is hoped that future use of gene specific tailored therapy and strategies will result in longer survival in cases showing poorer prognosis at present.
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ABSTRACT

History and classifications
The classification and genetics of acute myeloid leukaemias (AML) have undergone major changes since the 1970's as rapid advances in immunology and genetics have made significant progress in the understanding of this varied group of disorders ( fig. 1 ). The current 2008 WHO classifies precursor myeloid neoplasm into 7 major types and 24 subtypes' entities (Table 1) . 1 The first globally accepted AML classification was that of the French American British Classification (FAB; 1976) based on morphology and cytochemistry (% blasts and maturation).
2 The revised FAB; 1982 classification was similarly based on morphology and immunophenotyping. The WHO classification (2001) was based on morphology, immunophenotyping, cytogenetics and clinical presentation. 4 The current WHO (2008) classification is based on morphology, immunophenotyping, cytogenetics, clinical presentation and molecular biology. fig.2 ).
Immunophenotyping and karyotyping:
Immunophenotyping is rapidly replacing cytochemistry to differentiate acute leukaemias. They are useful to confirm myeloid or mixed phenotypic acute leukaemia lineage (MPAL; fig.3 ).
6 They are also useful to separate minimally differentiated acute myeloid leukaemia from acute lymphoblastic leukaemia and recognition of acute megakaryoblastic leukaemia. Strict criteria for immunophenotyping diagnosis need to be followed when investigating suspected MPAL as over use of immunophenotyping can lead to an over diagnosis of MPAL. About 50-60 % of de novo AML show karyotype abnormalities. By karyotyping AML are classified into low, intermediate and high risk groups (Table 2) . 7 Many AML cases have however normal karyotypes can still have genetic mutations. MDS related AML are now better understood due to karyotyping.
AML with recurrent genetic abnormalities
They have been separated as a distinct entity as they are associated with characteristic clinical, morphological and immunophenotypic features that form a clinicopathologicgenetic entity having prognostic significance. 8, 9 The most frequent are t(8;21), inv (16) 
Mutation analysis in AML
There are two types of genetic mutations in AML. 10 Class I mutations provide a proliferative and/or survival advantage and do not affect differentiation. They occur late in the disease or in relapse. They include: KIT, FLT3-ITD and FLT3-TKD. Class II mutations impair haematopoeitic differentiation and apoptosis. They occur early in the disease. They include: NPM1 and CEBPA ( fig.5 ).
Correlation of some mutations in AML with prognosis
NPM1 (nucleophosmin) mutations are the most common mutations in AML They occur in 30% of de novo AML and 50-60% of AML with normal cytogenetics. An NPM1 mutation without any FLT3-ITD mutation is associated with good induction therapy and better prognosis.
11,12 CEPBA (CCAAT binding protein enhancer alpha) mutations are seen in about 5-9% of AML. Lower relapse rate and improved survival are seen in CEPBA gene mutation. FLT3-ITD (FMS related tyrosine kinase 3 with internal tandem duplications) mutations are associated with shorter survival and unfavourable prognosis.
14 KIT mutations associated with t (8; 21), inv (16), t (16; 16) are associated with poorer prognosis. 15 Some of the other mutations and their present clinical utility are listed in table 4. 
Therapy related myeloid neoplasm
They are seen after cytotoxic chemotherapy and or radiotherapy. They are of two types: alkylating agent and radiation therapy related and Topoisomerase II inhibitor related.
Alkylating Agent/Radiation Therapy Related AML/ MDS
They occur 5-6 years after initiation of treatment with alkylating agents or radiotherapy. The risks are related to age and also to cumulative dosage. Two-thirds of cases present as MDS. One-third of cases present as overt AML with MDS features. All myeloid cell lines affected.
Dyserythropoiesis, ring sideroblasts are seen in 60% of cases (one-third in excess of 15% of erythroid cells). They also show hypo granulation and nuclear hypolobation of granulocytes. Dysplastic megakaryocytes are seen increased in 25% of cases. Basophils are increased in 25% of cases. Auer rods are seen in a minority of cases. Bone marrow biopsy is hypercellular in 50% of cases, normocellular in 25%, hypocellular in 25%, and shows fibrosis in 15%. phase. There may be a significant monocytic component. Most are acute monoblastic or myelomonocytic, occasionally acute promyelocytic leukemia or acute megakaryoblastic leukemia. The bone marrow is usually hypercellular. Usually balanced translocations involving 11q23 (MLL gene) and primarily t (9;11), t (11;19) , and t (6;11) are seen. Other translocations include t (8; 21), t (3; 21), inv (16), t (8;16).. They usually show good initial response to therapy, but relapses frequent and survival variable (especially poor with 11q23).
AML, not otherwise specified (AML NOS):
They include AML without recurrent genetic abnormalities and those without any myelodysplasia, post therapy related or Down's syndrome association ( fig.6 and table6) . Promonocytes in AML monoblastic variant are considered equivalent to blasts. Two new entities acute basophilic leukaemia and acute panmyelosis with myelofibrosis have been included with AML NOS.
Myeloid proliferations associated with Down's syndrome
Transient myeloid abnormalities often occur with DS, though AML related with DS is also seen. fig.7 ). AML) M7 is 500 times more common in DS than normal children. Half of leukaemias in DS are AML. ALL is 40 times more common in DS. AMKL is more common and confers a better prognosis in Down's syndrome. GATA-1 mutation occurs early in DS and is associated with increased risk of future leukaemia. GATA-1 mutations in DS with AML show better response to therapy and better overall prognosis compared to non-DS children with AML.
18
Microarray analysis and specific targeted therapy for AML Microarray analysis or gene profiling involve using large numbers of up to 13,000 oligonucleotide gene probes. The aim is an attempt to try to study the pathogenesis, predict prognosis and sub classify the different AML variants into meaningful groups. Genes with poor prognosis have been identified like HOXB2, HOXB5, PBX3, HOXA4, and HOXA10. However microarray methods are still yet to replace standard genetic methods. 19 Use of specific agents targeted against gain of function mutations like FLT3, JAK2 and cKIT are being developed using tyrosine kinase inhibitors The drugs include sorafenib, quizartinib, testaurtinib, midostaurin, pacritinib, PLX3397, and CCT137690. Aberrant proteins that are produced in AML like PLK1 can also be a target for specific therapy.20
CONCLUSION
The last decade has seen a large upsurge of interest and has resulted in many discoveries in the fields of acute myeloid leukaemias, cytogenetics and molecular genetics. A molecular classification of leukaemias is a distinct reality appearing in the distant horizon. Gene expression profiling, micro-RNA analysis, methylation analysis and whole genome sequencing analysis are expected to deliver more accurate descriptions of intricate molecular changes in AML. The data will help better understand the clinical behavior in distinct genetic groups resulting in better response to therapy and improved prognosis. The fields are exciting, it is hoped that all these events will lead to better understanding and management of these neoplasm, many of which still show dismal prognosis at present.
